Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on March 21, 2014. The report details a material definitive agreement entered into on February 14, 2014, and amended on March 21, 2014, with Lincoln Park Capital Fund, LLC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the potential capital raise capacity:
- Purchase Agreement Value: Up to $27,000,000 in shares of common stock.
- Liquidity Impact: The agreement provides a mechanism for the company to raise capital, though no funds were received at the time of this specific filing.
Material Changes
The material change reported is the execution of a letter agreement on March 21, 2014, which amended the original Purchase Agreement and Registration Rights Agreement. The amendment extends the deadline for the Company to file a Registration Statement with the SEC regarding the resale of the common stock by an additional 90 days.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard contingencies associated with equity financing. The primary contingency noted is the requirement to file a Registration Statement within the extended timeframe to facilitate the resale of shares to Lincoln Park.
Investor Verification Checklist
- Verify the current status of the $27,000,000 Purchase Agreement and whether any shares have been sold to Lincoln Park Capital Fund, LLC.
- Confirm the filing date of the Registration Statement required for the resale of shares under the amended 90-day extension.
- Review the company's current cash position and liquidity needs to assess the urgency of utilizing this financing facility.
- Check for any subsequent filings regarding the actual issuance of shares or further amendments to the agreement.